Skip to main content

EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition

Acquisition includes EsoBiotec’s world-leading in vivo delivery platform with potential to transform cell therapy

MONT-SAINT-GUIBERT, Belgium, March 17, 2025 (GLOBE NEWSWIRE) — EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN). The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes rather than the current process which takes weeks.

ENaBL uses highly targeted lentiviruses to deliver genetic instructions to specific immune cells, such as T cells, which programme them to recognise and destroy tumour cells for cancer treatment or autoreactive cells for potential use in immune-mediated diseases. This approach enables cell therapies to be administered through a simple IV injection and without the need for immune cell depletion.

Traditional cell therapies require cells to be removed from a patient, genetically modified outside the body, and then readministered to the patient as a medicine after immune cell depletion, typically taking weeks. By engineering immune cells directly within the patient’s body, the EsoBiotec in vivo approach has the potential to address many of the barriers associated with traditional cell therapies, reducing complexities and manufacturing timelines, thereby increasing access for patients.

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform. We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec will accelerate and expand the impact of our recent investments and marks a major step forward in realising our ambition to harness the full potential of cell therapy.”

Jean-Pierre Latere, PhD, CEO, EsoBiotec, said: “We look forward to working with AstraZeneca, a global leader in drug development, to advance our shared goal of bringing transformative cost-effective cell therapies to more patients globally. By combining our expertise and resources, we can accelerate the development of our in vivo platform which has a novel delivery technology we believe will have broad therapeutic applicability.”

EsoBiotec will become a wholly owned subsidiary of AstraZeneca, with operations in Belgium.

Financial considerations

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, and up to $575m in contingent consideration based on development and regulatory milestones.

The transaction is expected to close in the second quarter of 2025, subject to customary closing conditions and regulatory clearances.

Centerview Partners UK LLP is acting as exclusive financial advisor to EsoBiotec.

Cooley LLP is acting as legal advisor to EsoBiotec. Covington & Burling LLP is acting as legal advisor to AstraZeneca.

About EsoBiotec

EsoBiotec is a leading in vivo cell therapy company with the mission to make these innovative treatments more accessible, effective and affordable. By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases. EsoBiotec investors include Thuja Capital, UCB Ventures, Invivo Partners, Wallonie Entreprendre (WE), SambrInvest and Investsud.

EsoBiotec’s proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology. The vector has modifications which deliver specificity to immune cells, such as T cells, and also enable the vector to evade rapid elimination by the patient’s immune system. 

For more information on EsoBiotec, please visit www.esobiotec.com Follow us on LinkedIn.

Contacts

Investor Relations
Stephanie Carrington
ICR Healthcare
Stephanie.Carrington@icrhealthcare.com
(646) 277-1282

Media Relations
Alexis Feinberg
ICR Healthcare
Alexis.Feinberg@icrhealthcare.com
(203) 939-2225

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.